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Carbohydrate antigens have shown promise as important targets for developing effective vaccines and path-
ogen detection strategies. Modifying purified microbial glycans through synthetic routes or completely syn-
thesizing antigenic motifs are attractive options to advance carbohydrate vaccine development. However,
limited knowledge on structure-property correlates hampers the discovery of immunoprotective carbohy-
drate epitopes. Recent advancements in tools for glycan modification, high-throughput screening of biolog-
ical samples, and 3D structural analysis may facilitate antigen discovery process. This review focuses on
advances that accelerate carbohydrate-based vaccine development and various technologies that are
driving these efforts. Herein we provide a critical overview of approaches and resources available for rational
design of better carbohydrate antigens. Structurally defined and fully synthetic oligosaccharides, designed
based on molecular understanding of antigen-antibody interactions, offer a promising alternative for devel-
oping future carbohydrate vaccines.Carbohydrate antigens expressed by pathogens are often struc-
turally unique, and are thus potential targets for developing
vaccines and diagnostics. Vaccines based on capsular polysac-
charides (CPS) against multiple pathogenic bacteria have been
part of routine vaccinations for many years (Ada and Isaacs,
2003; Schumann et al., 2013; U.S. Department of Health and
Human Services, 2012). These vaccines are prepared using
CPS purified from bacterial cultures (European Medicines
Agency, 2009; World Health Organization, 2003; Costantino
et al., 2011). However, the presence of impurities that are coiso-
lated, such as cell-wall polysaccharides, have been associated
with side effects and hyporesponsiveness (Esposito et al.,
2010; Goldblatt et al., 1992; Musher et al., 1990; Poolman and
Borrow, 2011; Sen et al., 2005). Since isolated polysaccharides
are structurally heterogeneous, multiple purification and quality
control steps are required before an antigen can be formulated
in a vaccine (European Medicines Agency, 2009; World Health
Organization, 2000, 2003, 2005, 2006, 2009, 2012b). Efforts to
improve the efficacy and safety of these vaccines are important
to achieve comprehensive vaccination and eradication of the
respective pathogens. Synthetic oligosaccharides based on
the repeating units of CPS can be an attractive option to furnish
vaccines free of contaminants that have predictable clinical out-
comes (Seeberger and Werz, 2007). Designing vaccines based
on synthetic oligosaccharides is not straightforward and proves
to be scientifically challenging. The identification of an epitope
that will eventually induce protective immunity in vivo is a major
bottleneck. Innovative methodologies that can aid the design of
epitopes will render this process faster and less cumbersome.
Vaccines Based on Cell-Surface Glycans
Glycotopes or glycan B cell epitopes are segments of antigenic
polysaccharides recognized by the binding sites of membrane-
bound immunoglobulin (Ig) molecules (B cell receptor, BCR) on38 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rB cells. Polysaccharides are T cell-independent antigens that
can induce a short-term, IgM-dependent immune response,
but fail to efficiently elicit immunological memory (Mazmanian
and Kasper, 2006; Mond et al., 1995; Schumann et al., 2013;
Stein, 1992). Conjugation to a carrier protein converts glycans
to T-cell-dependent antigens that can induce the formation of
a long-lasting memory response. A T-cell-dependent immune
response is accompanied by the differentiation of polysaccha-
ride-specific B cells to plasma cells. Reinfection in the case of
a pathogen or boosting in the case of a vaccine then results in
proliferation of plasma cells and affinity maturation of secreted
antibodies (Abbas et al., 2012).
Glycoconjugate vaccines have been highly successful in pre-
venting infectious diseases caused by Neisseria meningitidis,
Haemophilus influenza, andStreptococcus pneumoniae (Garegg
and Maron, 1979; Johnson et al., 2010). Despite the effective-
ness of CPS-based vaccines, certain disadvantages are
encountered in vaccine manufacture. One major bottleneck is
the process of isolation and purification of pure capsular poly-
saccharides from pathogenic bacteria. Not all bacterial strains
can be cultured on sufficient scale (Rappuoli et al., 2011). The
production of polysaccharides requires efforts to optimize
growth conditions (Cimini et al., 2010; Gonc¸alves et al., 2002;
Jang et al., 2008; Jin et al., 2009). Furthermore, certain CPSs
are unstable and degrade during isolation or formulation pro-
cesses (Pujar et al., 2004; Sturgess et al., 1999). After isolation,
the purification of polysaccharides must be monitored on multi-
ple levels, as specified by guidelines set up by the regulatory
authorities (World Health Organization, 2000, 2003, 2005,
2006, 2009, 2012b). For instance, the existence of contaminants,
such as other cellular polysaccharides, proteins, and nucleic
acid, must be excluded. The structural integrity of the poly-
saccharide is assessed by wet chemical and instrumental ana-
lyses, such as nuclear magnetic resonance (NMR) spectroscopyights reserved
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et al., 2002). After limited depolymerization, chemical activation,
and conjugation, the absence of reactive groups on the glycan
fragments must be demonstrated. These and other steps of
quality control must be performed frequently during glycoconju-
gate manufacture, raising the cost per dose of the final vaccine.
Furthermore, it can be expected that vaccine formulations con-
taining chemically derivatized polysaccharides display artificial,
nonprotective epitopes that render the vaccine inefficient (Wes-
sels et al., 1998).
An important step toward the design of an effective vaccine is
the elucidation of the right antigenic epitope(s) that confer(s) the
production of antibodies that can protect the host from a path-
ogen (so-called protective epitopes). Even if information on a
putative protective epitope is available, it is nearly impossible
to purify the respective polysaccharide fragment to homogeneity
in order to maximize vaccine efficiency.
Synthetic Oligosaccharide-Based Vaccines
Synthetic oligosaccharides representing the repeating units of
CPS can be an attractive alternative to isolated polysaccharides
to produce structurally defined vaccines free of impurities (Schu-
mann et al., 2013). Since synthetic oligosaccharides can be
easily characterized, the manufacture of vaccines based on
these antigens is highly reproducible. In addition, access to
molecularly defined antigenic components may result in more
efficient final formulations while potentially lowering the costs
for vaccine development.
Recent years have seen extensive research in the field of
oligosaccharide synthesis that have led to the design of highly
potent antigenic targets (Berkin et al., 2002; Chong et al.,
1997; Costantino et al., 2011; Kudryashov et al., 2001; Martin
et al., 2013b; Morelli et al., 2011; Parameswar et al., 2009; Safari
et al., 2008; Schofield et al., 2002; Verez-Bencomo et al., 2004;
Zhu et al., 2009). The potency of synthetic oligosaccharide-
based vaccines is exemplified by the promising protective
effects of a Haemophilus influenzae type b (Hib) vaccine based
on synthetic oligosaccharides that is marketed in Cuba (Verez-
Bencomo et al., 2004).
Despite the progress concerning synthetic oligosaccharide-
based vaccines, designing the respective antigens remains chal-
lenging. As isolated polysaccharides are structurally complex,
the corresponding glycoconjugates most likely contain the
‘‘right’’ B cell epitopes needed to confer protective immunity.
Synthetic oligosaccharides, in contrast, are much smaller in
size; hence, the presence of protective epitopes in such an
antigen is not ensured. Identification of the right epitope is a
time-consuming step. Antigen design has traditionally been an
iterative process: synthetic targets are chosen based on the
chemical structure of repeating units and, after conjugation to
a carrier protein, evaluated in immunization experiments in ani-
mals (Robbins et al., 2009; Safari et al., 2012). If the resulting anti-
body response does not target the pathogen, different antigenic
constructs will have to be synthesized. Since the procurement of
synthetic oligosaccharides in ample quantities for mouse immu-
nization experiments (typically 10–20 mg of the deprotected
glycan) is resource intensive, this trial-and-error process in vac-
cine development is inefficient. Once the structure of a promising
antigen is known, however, chemical synthesis can be optimizedChemistry & Biolto provide large amounts of material (Kabanova et al., 2010;
Pozsgay et al., 2012). Recently, a chemoenzymatic method
was devised to generate gram amounts of tumor-associated
hexasaccharide antigens Globo H and SSEA-4, both of which
are interesting targets in the development of antitumor vaccines
(Tsai et al., 2013). Globo H is a good example of developing car-
bohydrate vaccines based on basic biochemical and clinical
findings and further optimizing the structure to a fully synthetic
epitope (Bremer et al., 1984; Gilewski et al., 2001). Glycoconju-
gates based on such a fully synthetic glycotope have been
advanced to early stages of clinical trials (Gilewski et al., 2001).
Thus, understanding the structure of a protective B cell
epitope is vital before immunization experiments are performed.
The currently available tools to map carbohydrate epitopes
(see below) can make use of small amounts of glycans for
screening purposes. Thus, the efforts of organic chemists can
be shifted from providing ample amounts of few structures to
generating whole libraries of structurally diverse glycans in
smaller quantities. Multiple approaches have been undertaken
to facilitate this process of generating diversity, such as the pro-
grammable one-pot glycosylation technique, which employs the
sequential activation of different glycosylating agents based on
reactivity differences to furnish oligosaccharides in one reaction
vessel without intermediate purification (Lee et al., 2006; Wu and
Wong, 2011). Enzymatic oligosaccharide syntheses have been
developed to generate a variety of complex glycan structures
(Nycholat et al., 2013; Tsai et al., 2013; Wang et al., 2013b),
although this approach is still somewhat limited to the more
common monosaccharides found in glycans from eukaryotes.
Automated solid-phase oligosaccharide synthesis has been
used to generate a plethora of synthetic oligosaccharides of
different complexities. Since the process of oligosaccharide
assembly is fully automated, target oligosaccharide structures
can be tailored toward the needs of the experimentalist using a
limited set of monosaccharide building blocks (Calin et al.,
2013; Plante et al., 2001; Seeberger and Werz, 2005, 2007). It
is thus conceivable that a large variety of potential antigens
can be generated much faster than by using traditional solu-
tion-phase oligosaccharide assembly.
Structural Attributes of Carbohydrate B Cell Epitopes
B cell epitopes can be classified into two groups: sequential
(continuous) epitopes and conformational (discontinuous) epi-
topes. A sequential B cell epitope is recognized as the primary
structure of an antigen, while a conformational B cell epitope
consists of residues that may be distantly separated in the pri-
mary structure and are recognized due to the close proximity
within the folded 3D structure (Arnon and Van Regenmortel,
1992). The nature of an epitope is of utmost importance during
antigen design: conformational epitopes are associated with a
distinct secondary structure of the glycan, a feat that may only
be achieved in longer sequences comprising multiple repeating
units. Thus, the synthetic effort compromises the applicability
of these long glycans as synthetic antigens. For instance, CPS
of group B streptococci (GBS) type III adopts a helical structure
above a length of five repeating units (Gonza´lez-Outeirin˜o et al.,
2005; Jennings, 2012; Woods and Yongye, 2012). Polysaccha-
ride fragments that are smaller than five repeating units fail to
elicit an efficient immune response (Jennings, 2012; MacKenzieogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 39
Figure 1. The Immunogenic Determinants of a Synthetic
Carbohydrate Antigen
Size/span of the epitope (1), terminal glycan residues (2), presence of
branching points (3), side chain functional groups (4), and number of repeating
units (5). L, preinstalled linker for conjugation.
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In contrast, oligosaccharides corresponding to S. pneumoniae
CPS have been found to be excellent immunogens even at
smaller sizes (Benaissa-Trouw et al., 2001; Jansen et al., 2001;
Safari et al., 2012). Other carbohydrate-based antigens induce
an efficient immune response at intermediate epitope lengths,
such as CPS fragments from Hib or certain Shigella strains
(Carlin et al., 1986; Chong et al., 1997; Peeters et al., 1992; Pha-
lipon et al., 2009; Pozsgay et al., 1999; Robbins et al., 2009;
Vince et al., 2003). The implications of these structural require-
ments are still poorly understood. In addition to glycan length,
important determinants for the viability of a carbohydrate antigen
comprise the stereochemistry of glycosidic linkages and the
arrangement of individual glycan components within a repeating
unit. In addition, the presence of branching points and different
substituents like phosphates, acetates, and pyruvates may be
crucial for immunogenicity, but render both design and synthesis
complex (Fusco et al., 2007; McNeely et al., 1998; Szu et al.,
1991; Werz and Seeberger, 2005). Critical factors determining
immunogenicity of a glycan are summarized in Figure 1.
Finding the Right Epitope: Approaches to Rational
Oligosaccharide Antigen Design
A major milestone in vaccine design is the induction of robust
titer of antibodies that cross-react with the native polysaccharide
and opsonize the pathogen. Thereby, it is desirable to reduce
the complexity of synthetic antigens to ensure feasibility of
large-scale synthesis while still maintaining the ability to raise a
specific, protective immune response. Novel concepts to unveil
protective epitopes include the screening of antisera on libraries
of synthetic glycans, reverse engineering of neutralizing anti-
bodies, and in silico antigen design (Figure 2).
Screening of Patient Sera for Antibodies against a
Synthetic Antigen Library
Sera of infected or vaccinated individuals provide invaluable in-
formation on epitopes recognized by the immune system. Tech-
niques to rapidly obtain this information have become available
only recently. Anti-capsular antibodies in sera are easily detect-
able by conventional binding assays, such as enzyme-linked40 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rimmunosorbent assay (ELISA). The structures of the precise
antigenic epitopes of CPS, however, are not uncovered by these
methods. Major progress in elucidating glycotopes has been
made by using glycan microarrays (de Paz and Seeberger,
2012; Feizi et al., 2003; Liu et al., 2009; Park et al., 2013; Rillahan
and Paulson, 2011; Smith et al., 2010). Thereby, minute amounts
of glycans of synthetic or natural origin are immobilized on sur-
faces via either covalent linkages or noncovalent adsorption.
After incubation with antisera, specific antibody-glycan binding
events can be detected by incubation with a fluorescence-
labeled secondary antibody (Anish et al., 2013a; Martin et al.,
2013a, 2013b). Careful design of the microarray printing pattern
by inclusion of oligosaccharides with different chain lengths,
frame shifts, and terminal glycan residues helps to deduce
meaningful inferences on the epitope of bound antibodies.
Polysaccharide-based vaccines have been highly efficient to
prevent infections with a variety of pathogenic bacteria. Consid-
erable efforts have been invested to generate synthetic variants
of these and other antigens, including H. influenzae, group B
Streptococcus, certain Shigella strains, and multiple serotypes
of S. pneumoniae (Benaissa-Trouw et al., 2001; Berkin et al.,
2002; Garegg and Norberg, 1982; Garegg et al., 1998; Hansson
et al., 2001; Parameswar et al., 2009; Verez-Bencomo et al.,
2004; Vince et al., 2003). Most of these antigens were pre-
pared and tested when mapping of carbohydrate epitopes was
not in experimental reach. Current endeavors by the carbohy-
drate research community are focused on the refinement of
these and further antigens to facilitate glycoconjugate vaccine
development.
One recent example for rational antigen design focused on the
development of vaccine candidates against Clostridium difficile.
This Gram-positive bacterium is the major cause of grave hospi-
tal-acquired (nosocomial), antibiotic-induced diarrhea (Rebeaud
and Bachmann, 2012). Several cell-surface glycans have been
identified on C. difficile, including two phosphodiester-contain-
ing polysaccharides (PS-I and PS-II) and lipoteichoic acid (LTA
or PS-III) (Ganeshapillai et al., 2008; Monteiro et al., 2013; Reid
et al., 2012). The respective synthetic oligosaccharide repeating
units to all of these glycans were prepared synthetically (Martin
et al., 2011, 2013a, 2013b; Oberli et al., 2011). Microarray
screening of both blood and stool samples of patients suffering
from C. difficile infections revealed the presence of antibodies
against all three structures to varying degrees (Martin et al.,
2013a, 2013b). Severe disease in patients correlated with low
levels of anti-PS-I IgA in stool samples, indicating a lack of pro-
tective immunity against C. difficile in these individuals. Further
evaluation of the recognized epitopes was enabled by the syn-
thesis of several PS-I oligosaccharide repeating unit substruc-
tures (Martin et al., 2013a, 2013b). Sera of reconvalescent
patients exhibited a significant increase of IgG levels against the
PS-I repeating unit a-Rhap-(1/3)-b-Glcp-(1/4)-[a-Rhap-(1/
3)]-a-Glcp-(1/2)-a-Glcp, as well as a di- and a triglucoside frag-
ment. Other substructures were recognized by serum and stool
antibodies in humans with and without a history of C. difficile
infection to similar degrees (Martin et al., 2013b). For further inves-
tigation of the role of PS-I in immunity against C. difficile, mice
were immunized with a PS-I-CRM197 conjugate, and the anti-
body response was evaluated by glycan microarray analysis.
Robust immune responses against a-Rhap-(1/3)-b-Glcp, aights reserved
Figure 2. Major Steps Involved in Rational Design of Synthetic Carbohydrate Vaccines
*Reprinted with permission from Oberli et al. (2010). Copyright (2010) American Chemical Society.
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this disaccharide is the smallest glycotope that confers recogni-
tion of the glycan by the immune system. Consequently, a glyco-
conjugate harboring the respective disaccharide hapten and
CRM197 as a carrier protein induced an immune response in
mice that cross-reacted with the PS-I pentasaccharide repeating
unit (Martin et al., 2013b). Thus, a-Rhap-(1/3)-b-Glcp is a candi-
date antigen to be applied in glycoconjugate vaccines against
C. difficile. It will be interesting to evaluate the potency of this
simplified antigen in a vaccination setting. Recent findings sug-
gest that the phosphodiester groups present in C. difficile PS-II
are crucial for eliciting an IgG response againstC. difficile bacteria
upon immunizationwith a PS-II-CRM197 conjugate (Adamo et al.,
2012). Further studieswill reveal whether this finding can be trans-
lated to PS-I oligosaccharides.
While glycoconjugate vaccines against bacteria are marketed,
recent years have seen tremendous progress in developing
antigens based on unique saccharide structures on the surface
of protozoan parasites, such as Leishmania, Trypanosoma, and
Plasmodium. The high variability of surface proteins often ham-
pers themanufacture of efficient protein-based vaccines against
these protozoa. Therefore, glycans are of paramount interest forChemistry & Biolvaccine research (Scherf et al., 2008; Stockdale et al., 2008). The
need for synthetic oligosaccharides as antigens is of special
relevance in these cases, as large-scale cultivation of protozoan
parasites and isolation of the respective glycans is impossible to
date (Visvesvara and Garcia, 2002).
Recently, the potential of cell-surface glycans for the detection
of Leishmania parasites in clinical samples has been established
(Anish et al., 2013b). Leishmania are transmitted by the bite of
sandflies and can cause symptoms affecting skin tissue (cuta-
neous leishmaniasis), but can develop into highly dangerous
visceral leishmaniasis, which is frequently associated with organ
failure and death (McCall et al., 2013). Development of a detec-
tion method was fuelled by the accessibility of synthetic oligo-
saccharides corresponding to Leishmania lipophosphoglycans
(LPG) (Anish et al., 2013b; Hewitt and Seeberger, 2001; Liu
et al., 2006). While the b-Galp-(1/4)-a-Manp-(1/P) repeating
unit LPG backbone is a conserved motif found on the parasite
surface, so-called capping oligosaccharides vary among dif-
ferent strains. Synthetic glycans corresponding to the capping
oligosaccharides of different strains were prepared, and binding
of human and canine antisera to these structures was assessed
(Anish et al., 2013b). A hybrid tetrasaccharide capping structureogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 41
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bound specifically by sera of Leishmania-infected dogs and
humans. Based on glycan microarray screening, the LPG
capping tetrasaccharide was selected for immunogenicity
studies. Antisera raised by the respective tetrasaccharide-
CRM197 conjugate were used to stain heat-killed L. chagasi
parasites, highlighting the relevance of synthetic glycans in
developing an immune response that binds to whole pathogens.
Based on synthetic oligosaccharides, the development of both a
diagnostic test and a glycoconjugate vaccine against Leish-
mania lies within reach.
Glycosylphosphatidylinositol (GPI) anchors are important gly-
colipids found on all eukaryotes that serve to link proteins to the
plasmamembrane. Protozoan parasites display a high density of
structurally unique GPI anchors on the cell surface (Paulick and
Bertozzi, 2008; Tsai et al., 2012). The nonvariable structures of
these glycans render them ideal for use in vaccination and
point-of-care diagnostic settings, especially in the case of Plas-
modium falciparum, the malaria-causing parasite. A number of
synthetic GPI anchors have been prepared (Azzouz et al.,
2010; Hewitt et al., 2002; Kwon et al., 2005; Tamborrini et al.,
2010; Tsai et al., 2012), harboring thiol linkers that can be chemo-
selectively coupled to microarray slides or carrier proteins. Syn-
thetic GPI anchors include oligosaccharides consisting of three
or four mannose residues (Man3-GPI and Man4-GPI, respec-
tively), as well as smaller structures (Kwon et al., 2005). Human
sera of malaria-endemic regions were assayed on microarray
slides containing these oligosaccharides (Kamena et al., 2008).
Robust antibody responses to longer GPI structures were
observed in all serum samples. It was further revealed that the
strength of this antibody response is stable throughout the wet
and dry seasons in the respective areas. When sera of nonex-
posed humans were assayed as a control, surprisingly, an
equally robust anti-GPI response to Man4-GPI was found, sug-
gesting that the respective oligosaccharides are notPlasmodium
specific. However, differences were seen in binding of sera to
Man3-GPI, with samples from malaria-endemic areas exhibiting
significantly increased antibody titers against these glycans. The
same trend was observed in human blood samples before and
after experimental Plasmodium challenge. A GPI-based malaria
vaccine candidate had previously shown excellent efficacy in
Plasmodium challenge studies in mice (Schofield et al., 2002).
The finding that subtle differences in the GPI glycan moiety
account for specificities in immune responses against protozoa
paves the way for carefully designed oligosaccharide-based
diagnostics and vaccines against these parasites.
Infections with Trypanosoma cruzi are of serious concern in
low-income regions of Latin America. T. cruzi is transmitted by
triatomine bugs and is the causative for Chagas disease.
Infected humans suffer from edema in the initial stages of the dis-
ease, followed by chronic symptoms such as neurodegeneration
and cardiomyopathies (Chuenkova and Pereiraperrin, 2011;
Nunes et al., 2013). Up to 10million people are currently affected
by Chagas disease (World Health Organization, 2012a), and
treatment is hampered by resistances of the parasite toward
the few available drugs (Mejia et al., 2012). T. cruzi is covered
by GPI-anchored proteins that carry unique mucin-type O-gly-
cans (Acosta-Serrano et al., 2001). Chemical synthesis of several
substructures corresponding to these O-glycans was recently42 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rreported (Ashmus et al., 2013). The glycans were chemically
conjugated to BSA and the glycoconjugates were immobilized
on 96-well plates to generate glycan arrays of a macroscopic
format. Incubation with human serum samples revealed specific
recognition of terminal a-Galp-(1/3)-b-Galp motifs by patient
antisera. In contrast, sera from healthy control individuals did
not contain antibodies that bind to these structures. Further-
more, a-Galp-b-Galp saccharides of different linkage types
were not recognized by patient sera, indicating that the 1/3-
linked disaccharide is a specific recognition motif of T. cruzi
surface glycans. Further experiments will reveal whether this
glycotope is a suitable starting point for diagnostic tests and
vaccination experiments. Particularly, cross-reactivity of these
glycans with antibodies against different pathogens must be
elucidated, preferentially in a study including more complex gly-
cans to assess specificity.
Designing Synthetic Glycan Antigens Based on
Structural Information of Carbohydrates and
Anti-Carbohydrate Antibodies
Recent progress in synthetic carbohydrate chemistry, bioin-
formatics, and analysis of carbohydrate-protein interactions
facilitates the 3D-structural interpretation of glycan-antibody
complexes. Numerous methods are currently in practice that
can aid the antigen design process. For instance, advancements
in structural methods, such as X-ray crystallography, NMR, or
small angle X-ray scattering (SAXS), are used to generate valu-
able information on the 3D structures of glycans and their inter-
action partners (Khan et al., 2011; Rademacher et al., 2007;
Vulliez-Le Normand et al., 2008). Information on the structural
requirements of glycan recognition can form the basis of
designing optimized carbohydrate vaccine candidates. Struc-
tural vaccinology is a newly emerging field and has already
contributed significantly to the development of modern pro-
tein-based vaccines (Dormitzer et al., 2012; Schneewind and
Missiakas, 2011). Adaptation of the structural vaccinology prin-
ciples to saccharides may reveal the nature of glycotopes that
are recognized by the host immune system, thereby facilitating
the design of more efficient vaccines. For instance, structural
understanding of the epitope helps to improve biochemical char-
acteristics of vaccine antigens and to select the combination of
glycan residues that are necessary to increase the breadth of
the immune response. Recently, Bundle and coworkers used
structural information to design a universal carbohydrate antigen
based on the antigenic determinants of A-type and M-type O
antigens of Brucella (Guiard et al., 2013). Studies on the nature
of antigenic determinants recognized by monoclonal antibodies
facilitated the design of one single oligosaccharide thatmay form
the basis for the diagnosis of Brucellosis.
When complex multiepitope antigens like polysaccharides are
conjugated to carrier proteins, the unfavorable immunodomi-
nance of few nonprotective epitopes is a key challenge in immu-
nization (Michon et al., 1991; Michon et al., 2005). For instance,
depolymerization of polysaccharides may lead to the presence
of neoepitopes that may hamper immunogenicity of natural gly-
cotopes (Csako et al., 1987; El Sabbagh et al., 1982). Structural
information on the binding of epitopes may help in decoding the
rules of immunodominance and provide the basis for manipu-
lating the antigen structure to render protective epitopes immu-
nodominant (Dormitzer et al., 2012).ights reserved
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cations that render purification tedious and decrease the stability
of the final vaccine formulation. The availability of validated
glycan sequences can provide the basis for atomic substitutions
in particularly labile positions and enhance vaccine stability.
Recently, a modified trisaccharide based on the repeating
unit of S. pneumoniae serotype 19F CPS (SP19F-CPS) was de-
signed and synthesized by Lay and coworkers (Legnani et al.,
2009). The SP19F-CPS consists of a trisaccharide repeating
unit, (/4)-b-D-ManpNAc-(1/4)-a-D-Glcp-(1/2)-a-L-Rhap-
(1-OPO3-/), with a phosphodiester bridge connecting the
repeating units. Based on a theoretical quantum mechanical
study on the conformational behavior of a-L-rhamnose-1-phos-
phate analogs, it was found that a carbasugar analog of L-rham-
nose is a suitable candidate to mimic the chemically labile
rhamnose-1-phosphate, preserving the geometrical properties
of the reference compound. Consequently, substitution of
L-rhamnose for the respective carbasugar in a synthetic 19F
CPS repeating unit rendered amore stable antigen with identical
conformational properties as the natural trisaccharide. A compe-
tition ELISA experiment based on binding of natural CPS and
anti-19F human polyclonal antiserum was employed to assess
the biological activity of the analog. The designed glycan mimic
showed biological activity similar to the natural repeating unit,
underlining the potential of rational design in refining the struc-
tural antigenic determinants of carbohydrate antigens. Lay and
coworkers recently expanded this concept toNeisseria meningi-
tidis serotype A (MenA) CPS. Poor hydrolytic stability of MenA
capsular polysaccharide, consisting of a-(1/6)-linked 2-acet-
amido-2-deoxy-D-mannopyranosyl phosphate repeating units,
is an impediment in the development of glycoconjugates based
on this antigen. Immunization of mice with hydrolysis-stable
structural carbasugar analogs of MenA CPS elicited antibodies
that were tested positive in a serum bactericidal assay (SBA)
against MenA, indicating the potential of this strategy to
generate potent antigens (Gao et al., 2013). Similar C-phospho-
nate MenA CPS analogs have been prepared by Oscarson and
coworkers (Teodorovic et al., 2006).
Another crucial step in structural glycotope design is the iden-
tification of key substituents that mask immune responses
toward a glycan. Neisseria meningitidis serotype C and Y
(MenC and MenY) capsular polysaccharides are good examples
for this challenge. MenC is a homopolymer of a-(2/9)-linked
sialic acids that areO-acetylated at position C-8 or C-7, whereas
MenY is a heteropolymer consisting of repeating disaccharides
of a-(2/4)-linked sialic acids attached to the 6 position
of glucose residues: a-D-Glcp-(1/4)-a-NeupNAc-(2/6). The
sialic acids on the purified polysaccharide are O-acetylated to
varying degrees at position C-9 or C-7 in a strain-dependent
manner (Fusco et al., 2007). However, upon storage in solution
after polysaccharide purification, these O-acetyl groups eventu-
ally migrate to the neighboring hydroxyl group (i.e., C-7 onMenC
and C-9 on MenY) (Lemercinier and Jones, 1996). Both preclin-
ical and clinical vaccination studies using deacetylated MenC
demonstrated that the O-acetyl group masks the protective
epitope in native CPS through steric hindrance or altered confor-
mations (Fusco et al., 2007).
Since modifications like acetyl groups can migrate or get lost
during polysaccharide purification, controlling and defining theChemistry & Bioldegree of these modifications in vaccines based on isolated
polysaccharides is challenging. This matter is of special rele-
vance if the modifications are crucial for the induction of a pro-
tective immune response. Synthetic oligosaccharides with
defined acetylation patterns can be an attractive option. Sialic-
acid-based synthetic vaccine candidates may accelerate this
process and lead to meningococcal vaccines (Chu et al., 2011;
Wang et al., 2013a). N. meningitidis serogroup W135 capsular
oligosaccharides ranging in length from di- to decasaccharides
have been synthesized. Sera from mice immunized with these
oligosaccharide-protein conjugates showed SBA activity, indi-
cating the immunoprotective potential of these vaccine candi-
dates (Wang et al., 2013a).
3D-structural information on oligosaccharide antigens is
becoming increasingly available. NMR spectroscopy and X-ray
crystallography are the most reliable techniques to reveal
glycan-antibody interactions at the molecular level. However,
typical Ka values of glycan-antibody interactions are weak, in
the 102–106 M1 range, complicating the cocrystallization of
both binding partners. In such instances, NMR is extremely use-
ful to obtain insights into the solution structure and the dynamics
of a ligand-antibody complex (Marcelo et al., 2012). However,
due to the intrinsic complexity and flexibility of carbohydrates,
a multidisciplinary strategy combining NMR parameters with
molecular modeling protocols should be followed in order to
generate reliable structural information (Marcelo et al., 2012).
The method of choice to uncover structural requirements of
glycan-antibody interactions depends on the particular problem
and the required structural information. Generally, two broader
approaches may be distinguished: ligand based and receptor
based.
In ligand-based structural glycobiology, changes in the
parameters of the ligand are monitored upon passing from the
free to the bound state (Marcelo et al., 2012). Thereby, NMR
techniques are often preferred over other biophysical methods.
NMR measurements can be employed to detect binding, to
elucidate the bound conformation of the glycan, to map
the bound epitope, and to provide information on molecular
dynamics (Marcelo et al., 2012). Combinations of transferred
nuclear Overhauser effect spectroscopy (TR-NOESY) (Ni and
Zhu, 1994) and saturation transfer difference (STD) (Mayer and
Meyer, 1999; Mayer and Meyer, 2001) NMR experiments have
been employed extensively to study the conformations of carbo-
hydrates bound to antibodies and to define interacting epitopes
(Cle´ment et al., 2006; Herfurth et al., 2005; Maaheimo et al.,
2000; Oberli et al., 2010; Rademacher et al., 2007). We revealed
the structural features of the interaction between a Bacillus
anthracis tetrasaccharide containing three rhamnoses and a
unique terminal anthrose unit and a monoclonal antibody
(MTA1-3) by STD NMR (Oberli et al., 2010). A combined
approach involving glycan array screening, surface plasmon
resonance (SPR), and STD NMR revealed structural insights
into the molecular events of carbohydrate-antibody interactions.
The use of severalB. anthracis oligosaccharides demonstrated a
crucial role of the anthrose residue in recognition (Oberli et al.,
2010).
Transferred NMR methodologies, such as TR-NOESY (Ni and
Zhu, 1994) and TR-ROESY (Arepalli et al., 1995), are employed
by different groups to deduce the bound conformation ofogy 21, January 16, 2014 ª2014 Elsevier Ltd All rights reserved 43
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bined TR-NOESY and modeling data to deduce the bound
conformation of a Salmonella paratyphi oligosaccharide com-
plexed to an antibody (Milton and Bundle, 1998). This antibody
recognized the repeating unit of the Salmonella serogroup B O
antigen a-D-Galp-(1/2)[a-D-Abep-(1/3)]-a-D-Manp-(1/4)-
a–L-Rhap-(1/3). It was shown that the monoclonal antibody
(mAb) prefers one high-energy conformation of the a-D-
Manp(1/4)-a-L-Rhap glycosidic linkage. The availability of
such refined 3D-structural information of bound glycans will
aid the optimization and design of immunoprotective oligosac-
charide motifs.
Reverse engineering of a protective monoclonal antibody
(mAbC3.1) was the basis for the design of novel glycoconjugates
en route to vaccines against Candida albicans (Bundle et al.,
2012). The antibody was found to bind b-(1/2)-linked manno-
pyranose homo-oligomers. The inhibitory activity of mAb binding
to the native antigen reached a maximum for a trisaccharide and
then rapidly decreased with increasing oligosaccharide length
(Bundle et al., 2012). This inhibition pattern is in stark contrast to
the paradigm of oligosaccharide-antibody interactions, dictating
that typically longer oligosaccharides are best accommodated in
the antibody binding pocket (Ma¨kela¨ et al., 1984). Sequential
chemical mapping by functional group replacement led to the
identification of a disaccharide as a minimum sized glycotope
for mAb C3.1. This disaccharide was synthesized and conju-
gated to a carrier protein. Synthesis of deoxygenated and meth-
ylated glycan congeners enabled the mapping of polar contacts
between the antibody and the b-mannan disaccharide epitope.
Protective immunity induced by immunization with rationally de-
signed shorter oligosaccharide antigens is a great boost to the
field of synthetic glycoconjugate vaccines. The scope of this
work was further expanded recently by augmentation of the
immunogenicity of a b-mannan trisaccharide antigen by active
targeting of dendritic cells via Dectin-1, a C-type lectin receptor
involved in antigen capture and processing (Lipinski et al., 2013).
A shortcoming of NMR-based epitope mapping is the restric-
tion on certain tight kinetic requirements. Such methods work
optimally when the off rate is fast in the relaxation time scale of
the ligand. For slow dissociation kinetics, conventional NMR
methods do not provide adequate information. Consequently,
STD and TR-NOESY methods are not useful for dissociation
constants in the low micromolar or nanomolar ranges, (Marcelo
et al., 2012) and the observation of the parameters associated
with the receptor becomes the method of choice.
In a receptor-based approach, methods of structural bio-
chemistry are employed to map the antigen combining sites or
complementarity determining regions (CDRs) of an antibody.
However, antibodies are large macromolecules, and due to their
weaker interactions, gaining detailed structural information of a
carbohydrate-antibody complex represents a real challenge.
NMR experiments coupled with isotope labeling are frequently
employed to gain insights into antibody binding surfaces (Kato
et al., 2010). X-ray crystallography would provide structural
information on antigen combining sites with highest resolution.
However, only few crystal structures of carbohydrate-antibody
complexes have been solved thus far (Evans et al., 1995; Nagae
et al., 2013; Villeneuve et al., 2000; Vulliez-Le Normand et al.,
2008). Various studies have demonstrated that carbohydrate44 Chemistry & Biology 21, January 16, 2014 ª2014 Elsevier Ltd All rbinding sites of an anti-glycan antibody can vary significantly in
the epitope size they accommodate. Cocrystal structures of
carbohydrate-bound antibodies reveal the span of the bound
epitope and structural details of important residues that interact
with antibody CDRs. Relatively small oligosaccharides occupy
the binding site in reported structures (Nagae et al., 2013; Ville-
neuve et al., 2000), while few reports of larger epitopes exist
(Vulliez-Le Normand et al., 2008). In one special case, a(2/8)-
polysialic acid apparently occupies an exceptionally long bind-
ing site (Evans et al., 1995). Two key examples demonstrating
the receptor based approach in carbohydrate antigen design
involve Vibrio cholerae O1 antigen (Villeneuve et al., 2000) and
synthetic O antigen fragments from serotype 2a Shigella flexneri
(Vulliez-Le Normand et al., 2008).
Vibrio cholerae serogroups differ in their lipopolysaccharide
(LPS) structures. Serogroup O1 causes most cholera outbreaks
worldwide and includes two major serotypes: Ogawa and Inaba.
The two types differ only by a single 2-O-methyl group that is
present at the nonreducing terminal perosamine unit of the
Ogawa O-specific polysaccharide (O-SP) and is absent in the
Inaba O-SP. The crystal structure of a murine protective anti-
body specific for Ogawa LPS was solved in its unliganded
form and in complex with synthetic fragments of the Ogawa
O-SP (Villeneuve et al., 2000). The upstream terminal O-SP
monosaccharide was found to be the primary antigenic determi-
nant and rationalized the serotype specificity of anti-Ogawa
antibodies. These insights provided a basis for the development
of a synthetic oligosaccharide anticholera vaccine.
The repeating unit of theShigella flexneri serotype 2aOantigen
is a branched pentasaccharide with the sequence a-L-Rhap-
(1/2)-a-L-Rhap-(1/3)-[a-D-Glcp-(1/4)]-a-L-Rhap-(1/3)-b-
D-GlcNAcp (1/2). The crystal structures of two immunogenic
synthetic oligosaccharides in complexwith a protective Fab frag-
ment (F22-4) have been reported (Vulliez-Le Normand et al.,
2008). F22-4 binds to an epitope generated by two consecutive
pentasaccharide repeat units. Six sugar residues out of a contig-
uous nine-residue segment were shown to form direct contacts
with the CDRs. The nonreducing rhamnose and both branching
glucosyl residues from the two reproductive units (RUs) were
indicated as crucial components of the epitope. These results
have implications for vaccine design as they suggest that a min-
imum of two RUs of synthetic serotype 2a oligosaccharides are
required as O antigen glycotopes.
Structural information of antigen binding surfaces of an anti-
body can form the basis for designing better antigens. Broadly
neutralizing anti-HIV mAb 2G12 is a well-studied example.
mAb 2G12 recognizes a conserved and unusually dense cluster
of oligomannose residues (terminal a-D-Manp-(1/2)-Man resi-
dues) on gp120, an envelope protein of HIV-1. Both liganded and
unliganded crystal structures of this antibody have been re-
ported (Calarese et al., 2003), and this information has been
used extensively as a template to develop strongly binding
glycan ligands (Lee et al., 2004).
The 2G12 antibody adopts a unique domain-swapped tertiary
structure (Calarese et al., 2003). This arrangement produces an
array of antibody combining sites in proximity to one another.
Two conventional combining sites formed by heavy (VH) and light
(VL) variable domains sandwich an unconventional site com-
posed of two neighboring VH domain residues (Figure 3). Theights reserved
Figure 3. The Structure of Man9GlcNAc2 on
HIV Protein gp120 Interacting with the
Broadly Neutralizing mAb 2G12
Adapted from Lee et al. (2004).
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that the conventional binding sites are occupied by the D1
arms of the Man9GlcNAc2 moieties. The terminal a-D-Man
(1/2)-Man residues establish 85% of the contacts with the
binding site. The nonconventional site is occupied by the D2
arms of neighboring Man9GlcNAc2 moieties. This detailed 3D-
structural information triggered the design of multivalent ligands
that may form the basis of a synthetic high-mannose oligosac-
charide vaccine for HIV (Enrı´quez-Navas et al., 2011; Lee et al.,
2004; Wang et al., 2004, 2007). For instance, Lee et al. designed
and synthesized oligomannoses by a reactivity-based, modular
one-pot synthesis method that requires a minimal number of
building blocks (Lee et al., 2004). Thereby, novel synthetic
oligomannose glycotopeswere reported that effectively inhibited
the binding of 2G12 to gp120, indicating the vaccine potential of
these glycans. Recently, numerous potent and broadly neutral-
izing antibodies such as PG 127 and PG 128 that recognize HIV
glycan shield have been reported (Pejchal et al., 2011). Thus,
HIV surface glycans are emerging as a major target for devel-
oping antibody based therapeutics and prevention strategies.
Computational Approaches to the Rational Design of
Carbohydrate Antigens
Establishing structure-function correlations for carbohydrate
antigenicity is a rapidly emerging area. Understanding the struc-
tural features of antigenic carbohydrates is a key step in this re-
gard. The high-flexibility, complex shape and dynamic properties
of pyranose rings and the presence of functional groupmodifica-
tions render structure acquisition challenging (Woods and Yon-
gye, 2012). Computational methods can be employed to study
structural determinants of affinity, specificity, and antigenicity
where traditional 3D-structural methods reach their limits.
In silico simulations can provide atomic level interpretations of
binding events that are experimentally inaccessible. Computa-
tional methods help deducing the roles of enthalpy and entropy
in driving oligosaccharide antigenicity. Such insights are crucial
while selecting the right candidate for synthesis.
Established structural methods, such as X-ray diffraction or
NMR spectroscopy, face enormous challenges when applied
to the study of large cell-surface glycans. Although NMR tech-Chemistry & Biology 21, January 16, 201niques can be used for studying less
homogeneous isolated polysaccharides,
molecular weight limitations greatly limit
the application of NMR-based methods
in large antibody-polysaccharide com-
plexes. Moreover, NMR data alone are
generally insufficient to completely char-
acterize carbohydrate conformations
and need to be complemented by insight
from in silico methods, such as molecular
dynamics (MD) simulations (Woods and
Yongye, 2012).
While no method alone is adequate to
characterize either the conformation ofan oligosaccharide or its complex with a protein, the combina-
tion of experimental biophysical techniques with current com-
putational methods offers an opportunity to deduce structure-
function relationships in carbohydrate-antibody interactions.
A multidisciplinary approach for deciphering crucial glycan
immunogenicity features was brought to bear on the polysialic
acid-based Neisseria mengitidis serotype B capsular polysac-
charide (MenB PSA). The immune system frequently elicits a
response to long and extended glycotopes so that autoreactivity
to short mammalian glycan motifs can be avoided. The two best
examples for the case are constituted by CPS of group B
N. meningitidis and group B Streptococcus (Jennings, 2012).
Computational approaches were instrumental in defining the
extended epitopes of these antigens. MenB PSA consists of
chains of a-(2/8)-polysialic acid, and due to structural similarity
to polysialic acids on neural cell adhesion molecules (Finne and
Ma¨kela¨, 1985), MenB PSA is often considered as a self-antigen
by the immune system. By adoption of aggressive immunization
strategies, specific antibodies recognizingMenB PSA have been
raised (Jennings, 2012). An extended helical epitope of MenB
PSA was identified using a combination of inhibition studies,
NMR, and conformational analysis using potential energy calcu-
lations (Jennings, 2012). MenB PSA required an unusually long
motif to show efficient binding to antibodies, indicating the
conformational nature of antigenic glycotopes. Conformational
studies showed that, although PSA exists predominantly in
the random coil form, the polysaccharide can readily adopt
extended helical conformations. Detailed studies also revealed
that carboxylate groups were important for maintaining the
conformation and that substitution ofN-acetyl with larger N-pro-
pionyl groups did not affect binding (Brisson et al., 1992). A
crucial role of this large extended conformation in binding to
antibodies was confirmed by X-ray analysis of an unliganded
Fab fragment. Although conformational studies showed that
the conformational epitope is only a minor contributor to the
total number of possible epitopes formed by PSA (Brisson
et al., 1992), the immune response was dominant for this less
populated epitope. The reluctance of the immune system to pro-
duce antibodies associated with the more populated random4 ª2014 Elsevier Ltd All rights reserved 45
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this finding, an artificial antigen was designed carrying N-propi-
onates instead of N-acetates (Jennings, 2012).
MD simulations helped to define the conformational epitope of
bacterial polysaccharides fromGBS (Woods and Yongye, 2012).
A complete computational analysis of GBS, in terms of its
interaction with mAb 1B1, characterization of the solution con-
formation of the antigenic fragments, and characterization of
the putative immune complex was reported (Kadirvelraj et al.,
2006; Woods and Yongye, 2012). This work provided the struc-
tural and energetic explanation for the observed lack of cross-
reactivity between GBS and its close relative Pneumococcus
type 14. Thereby, the bactericidal epitope (bound to mAb 1B1)
was identified as equivalent to the solution conformational
epitope (Kadirvelraj et al., 2006).Conclusions and Outlook
Carbohydrate antigens are important targets for the develop-
ment of vaccines and pathogen detection strategies. Vaccines
based on isolated glycan structures have helped to prevent
deadly infectious diseases and to approach the nearly complete
eradication of certain pathogens. While it is conceivable that
the majority of efficacious polysaccharide-based vaccines will
still be marketed several decades from now, synthetic oligo-
saccharide antigens can help targeting those diseases that are
difficult to tackle with purified glycans due to stability or scalabil-
ity issues. Although numerous diseases fall in this category, for
socioeconomic reasons, development of vaccines for such
infections is generally considered nonviable. Concerted efforts
of nonprofit organizations, big vaccine companies, and regula-
tory agencies are required to achieve this goal. Solving major
technological bottlenecks may further facilitate the process.
Inclusion of epitope selection steps during antigen manufacture
will not only speed up the developing process, but also signifi-
cantly reduce the cost for the generation of a vaccine. Develop-
ment of novel protein-free synthetic carrier molecules may also
be relevant, considering the carrier-mediated epitope suppres-
sion induced by carrier proteins employed in conventional
vaccines.
Modifying purified microbial carbohydrates through chemical
synthesis or completely procuring glycan fragments through
organic synthesis facilitated the antigen discovery process. An
improved understanding of structural features that determine
antigenicity is a prerequisite for efficient vaccine design. The
identification of key epitopes that protect from a potential
immune challenge or infection is a crucial milestone. Multidisci-
plinary approaches involving advanced oligosaccharide synthe-
sis, glycan array screening, and biophysical and computational
methods have been utilized by many groups to attain this goal.
The scope of this approach has been demonstrated with
numerous carbohydrate antigens. Nevertheless, fully synthetic,
rationally designed carbohydrate antigen is still not available,
and recent advancement in synthetic, structural, and computa-
tional methods may help to meet this goal.ACKNOWLEDGMENTS
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